Cited 8 times in
Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강창무 | - |
dc.contributor.author | 이우정 | - |
dc.contributor.author | 정재욱 | - |
dc.contributor.author | 황호경 | - |
dc.contributor.author | 윤미진 | - |
dc.date.accessioned | 2017-11-02T08:39:09Z | - |
dc.date.available | 2017-11-02T08:39:09Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154720 | - |
dc.description.abstract | PURPOSE: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. METHODS: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18FDG uptake than that of renal calyx was regarded as Non-K type. RESULTS: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUVmax,P<0.001), metabolic tumor volume (MTV2.5, P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior disease-free survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). CONCLUSIONS: Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/classification | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/diagnostic imaging* | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/mortality | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/surgery | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18/metabolism | - |
dc.subject.MESH | Fluorodeoxyglucose F18/pharmacokinetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pancreatectomy* | - |
dc.subject.MESH | Pancreatic Neoplasms/classification | - |
dc.subject.MESH | Pancreatic Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Pancreatic Neoplasms/mortality | - |
dc.subject.MESH | Pancreatic Neoplasms/surgery | - |
dc.subject.MESH | Positron-Emission Tomography/methods* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiopharmaceuticals/metabolism | - |
dc.subject.MESH | Radiopharmaceuticals/pharmacokinetics* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Jae Uk Chong | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | Jin Ho Lee | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Woo Jung Lee | - |
dc.identifier.doi | 10.1371/journal.pone.0172606 | - |
dc.contributor.localId | A02993 | - |
dc.contributor.localId | A03710 | - |
dc.contributor.localId | A04497 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A00088 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 28235029 | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.alternativeName | Chong, Jae Uk | - |
dc.contributor.alternativeName | Hwang, Ho Kyoung | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.contributor.affiliatedAuthor | Chong, Jae Uk | - |
dc.contributor.affiliatedAuthor | Hwang, Ho Kyoung | - |
dc.contributor.affiliatedAuthor | Yun, Mi Jin | - |
dc.contributor.affiliatedAuthor | Kang, Chang Moo | - |
dc.citation.title | PLoS One | - |
dc.citation.volume | 12 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e0172606 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.12(2) : e0172606, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 44201 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.